Bruker Co. (NASDAQ:BRKR) Declares Quarterly Dividend of $0.05

Bruker Co. (NASDAQ:BRKR) announced a quarterly dividend on Monday, February 24th, Wall Street Journal reports. Investors of record on Monday, March 17th will be given a dividend of 0.05 per share by the medical research company on Friday, March 28th. This represents a $0.20 annualized dividend and a yield of 0.39%. The ex-dividend date is Monday, March 17th.

Bruker has raised its dividend by an average of 7.7% per year over the last three years. Bruker has a dividend payout ratio of 6.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Bruker to earn $3.15 per share next year, which means the company should continue to be able to cover its $0.20 annual dividend with an expected future payout ratio of 6.3%.

Bruker Price Performance

Bruker stock opened at $51.89 on Tuesday. Bruker has a 12-month low of $48.07 and a 12-month high of $94.86. The stock has a market cap of $7.87 billion, a P/E ratio of 68.28, a PEG ratio of 2.16 and a beta of 1.16. The company has a 50-day moving average price of $56.63 and a 200 day moving average price of $59.95. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Sell-side analysts anticipate that Bruker will post 2.69 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Bank of America lifted their price target on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Wells Fargo & Company dropped their price target on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective for the company in a report on Thursday, December 5th. TD Cowen dropped their price objective on shares of Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a report on Wednesday, November 6th. Finally, Guggenheim restated a “buy” rating on shares of Bruker in a report on Monday. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.